Moderna was trading around $22 in late 2025. It closed October 6 at $187.46. That move did not come from a vaccine rebound or a deal with a large pharma buyer. It came from a single clinical trial result that, if the detailed data holds, rewrites what mRNA technology is capable of.
The Business
Moderna’s original identity as a COVID vaccine maker is mostly priced out of the investment case by now. The company’s mRNA-1010 flu vaccine has been under FDA review, with an August 5, 2026 PDUFA goal date, potentially adding an incremental revenue stream. But the 2026 move is driven entirely by oncology. Intismeran autogene uses tumor sequencing to create a bespoke mRNA encoding up to 34 neoantigens, aiming to amplify tumor-specific T-cell immunity when combined with PD-1 blockade. Each dose is unique to one patient’s cancer. That is not how drugs have been made before at scale.
Why Wall Street Is Paying Attention
On August 19, Merck and Moderna announced that intismeran autogene met both the primary and a key secondary endpoint of the Phase 3 INTerpath-001 trial in patients with completely resected high-risk melanoma, representing the first positive late-stage readout for individualized mRNA cancer therapy.
Five-year follow-up data from the earlier Phase 2b trial, presented at the 2026 ASCO meeting, showed the combination reduced the risk of recurrence or death by 49% compared with pembrolizumab alone. That is the number the market is pricing in. The October 24 ESMO Presidential Symposium will be the first time full Phase 3 hazard ratios and survival curves are publicly presented.
Then, on October 9, Moderna is set to rejoin the Nasdaq-100, replacing Warner Bros. Discovery, with index funds tracking the benchmark expected to add shares around that date. That mechanical buying adds near-term demand independent of the clinical story.
What’s Driving the Opportunity
The bear case on Moderna through most of 2025 was that the company was burning cash with no near-term growth engine. The Phase 3 win changes that framing entirely. One analyst estimates intismeran could reach average revenue of $1.4 billion by 2032, but that figure assumes a single indication. Merck and Moderna are testing the therapy across multiple tumor types, meaning the melanoma win is the first proof of concept, not the ceiling.
Moderna narrowed its net loss to $782 million from $825 million year over year, and improved its 2026 GAAP operating expense outlook by about $200 million. The company is not profitable today, but the trajectory is moving in the right direction before a potential blockbuster approval.
What Could Go Wrong
The October 24 ESMO presentation carries real binary risk. The topline Phase 3 win is confirmed, but detailed hazard ratios, subgroup analyses, and the depth of the survival benefit will either validate the stock’s roughly $75 billion market cap or compress it sharply. If hazard ratios and survival curves disappoint relative to the 49% recurrence-free survival benefit from Phase 2b, the multiple could compress overnight.
Citi is already flagging the gap between enthusiasm and fundamentals. Citigroup downgraded Moderna to Sell with an $80 target, citing valuation concerns after the rally. Citi’s model assumes annual cancer revenue of about $26 billion is needed to sustain a stock price near $200. That is an aggressive assumption for a therapy that has not yet filed for regulatory approval.
The Bottom Line
Moderna is not a comfortable hold at $190. The company is losing money, the regulatory path to approval is at least a year away, and the October 24 data presentation can go either direction. What makes it the most compelling biotech situation right now is that the Phase 3 trial already succeeded at the topline level, the Oct. 9 Nasdaq-100 addition adds a structural bid, and the detailed data presentation is 17 days out. Investors with a defined risk tolerance and an understanding of the binary nature of that event have a concrete catalyst to trade against.
